TJ-41 is indicated for the following symptoms/conditions of patients having delicate constitution, reduced digestive func-tions, and severe fatigability of limbs: Summer emaciation, reinforcement of physical strength after illness, tuberculosis, anorexia, gastroptosis, cold, hemorrhoid, anal prolapse, uterine prolapse, impotence, hemiplegia, and hyperhidrosis
Conditions
Interventions
investigational material(s)
Generic name etc : Hochuekkito
INN of investigational material : -
Therapeutic category code : 52- Chinese medicines
Dosage and Administration for Investigational material
Sponsors
Tsumura & Co.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: TJ-41 is indicated for the following symptoms/conditions of patients having delicate constitution, reduced digestive func-tions, and severe fatigability of limbs: Summer emaciation, reinforcement of physical strength after illness, tuberculosis, anorexia, gastroptosis, cold, hemorrhoid, anal prolapse, uterine prolapse, impotence, hemiplegia, and hyperhidrosis. The usual adult dose is 7.5 g/day orally in 2 or 3 divided doses before or between meals. Patients who have never taken TJ-41 in the past, or have been 6 months or more since the last dose.
Exclusion criteria
Exclusion criteria: -
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety Presence or absence of adverse event, adverse event name, onset date, severity, treatment of TJ-41, outcome and outcome date, causal relationship with TJ-41, treatment details for adverse event. | — |
Secondary
| Measure | Time frame |
|---|---|
| other efficacy Effectiveness; improvement, no change, worse, undecidable Treatment satisfaction: fully satisfactory treatment, almost satisfactory treatment, unsatisfied treatment only, treatment not being carried out, undecidable | — |
Countries
Japan
Outcome results
None listed